![]() More information is available at follow us on Twitter and LinkedIn. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. “As we head into the key second half of 2022, we look forward to working closely with Michael and are delighted to welcome him to our board.” On behalf of the entire UNITY team, I would like to thank him for his dedicated service and important contributions,” said Keith Leonard, chairman of the board of UNITY Biotechnology. “Graham has been with UNITY through key parts of its evolution and has contributed enormously to the Company, especially as Chair of Audit Committee. Cooper has stepped down from the board of directors. He also serves as Treasurer on the Board of OUTbio Bay Area, Inc., a non-profit organization for LGBTQ+ professionals in the biotech and related industries.Ĭoncurrent with Mr. Samar obtained his MBA from Villanova University and his BS in finance from Bryant University. His prior experience includes serving as Vice President of Finance and Site Head for the South San Francisco facility at Acorda Therapeutics Director of Financial Planning and Analysis at Onyx Pharmaceuticals Senior Finance Director, Global Planning and Analysis at Agennix, and increasingly senior roles within finance at Johnson & Johnson Pharmaceutical R&D. Samar currently serves as chief financial officer of Assembly Bio, having been promoted from SVP of finance and business operations. With his strong background in biotech finance and operations, combined with an energetic fresh perspective and track record of execution, Michael’s strategic perspective will be vital as we focus on executing on our UBX1325 studies in DME and AMD and delivering key readouts this year,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY Biotechnology. ![]() “We’re thrilled to add Michael to UNITY’s board of directors. (“UNITY”), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Michael Samar, current chief financial officer at Assembly Bio, has been appointed to the Company’s board of directors as its chair of the audit committee and a member of its compensation committee. SAN FRANCISCO, (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |